Warsaw

• VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended
  2023-509233-39-00 4 2022-01-20 Moderately to Severely Active Ulcerative Colitis
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) Ended
  2023-509018-12-00 5 2021-12-17 Moderately to severely active Ulcerative Colitis (UC)
• MENACWY=MEN7B-003 Ended
  2023-506449-40-00 9 2021-11-29 Infections, Meningococcal
• A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended
  2024-514405-65-00 4 2021-11-22 Atopic Dermatitis
• A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended
  2024-511999-32-00 9 2021-11-19 Advanced/Metastatic EGFR-expressing Cancers
• A clinical study of tulisokibart in people with Crohn’s disease (MK-7240-006) Ended
  2023-509742-35-00 4 2021-11-17 Crohn's disease
• Evaluation of frequency occurrence persistent pulmonary hypertension of newborns treated by salbutamol Ended
  2024-515216-46-00 11 2021-11-15 Breathing disorders as a cause of neonatal respiratory failure
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 4 2021-11-08 Classical Hodgkin Lymphoma
• A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended
  2024-514934-19-00 5 2021-11-08 Post-surgical neuropathic pain
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
• Asciminib treatment optimization in ≥ 3rd line CML-CP Ended
  2024-511381-36-00 5 2021-10-13 Chronic Myelogenous Leukemia in chronic phase (CML-CP)
• Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended
  2024-517389-40-00 4 2021-10-06 acute lymphoblastic leukemia
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su … Ended
  2024-512142-42-00 5 2021-10-05 Psoriatic Arthritis
• A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended
  2023-509741-12-00 4 2021-09-23 Ulcerative Colitis
• A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended
  2024-512879-13-00 5 2021-09-23 Neovascular age-related macular degeneration (wet AMD)
• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 4 2021-09-13 Advanced solid tumors
• A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the … Ended
  2024-513839-24-00 5 2021-09-07 Congenital Thrombotic thrombocytopenic purpura (cTTP)
• A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe pla … Ended
  2023-509832-24-00 4 2021-08-30 Moderate to Severe Plaque Psoriasis
• A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea … Ended
  2023-504156-10-00 5 2021-08-13 Plaque Psoriasis.
• This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) Ended
  2024-511503-41-00 3 2021-08-13 Advanced or metastatic solid tumors
• Phase 2 First-Line ES-SCLC Platform Study Ended
  2023-506538-56-00 4 2021-08-12 First-line treatment of participants with extensive-stage small cell l

Showing 1,561–1,584 of 1,708 trials